GlassScriptPhysician profile
Mamta Parikh
NPI 1649595026
$32,756.64
in general payments reported to CMS, 2019-2025
21 companies · $2,793 in 2025
The $2,793 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $6,862 · 2020: $1,474 · 2021: $8,179 · 2022: $78.37 · 2023: $9,044 · 2024: $4,326 · 2025: $2,793.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $12K · Honoraria: $1,980 · Food and Beverage: $1,240 · Travel and Lodging: $962 · Education: $35.06.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $11,946.00 |
| Honoraria | $1,980.00 |
| Food and Beverage | $1,240.40 |
| Travel and Lodging | $961.82 |
| Education | $35.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exelixis INC. | $7,280.96 | 2021-2024 | Cabometyx |
| Genzyme Corporation | $6,636.83 | 2023 | |
| Astrazeneca Pharmaceuticals LP | $5,235.06 | 2021-2025 | Imfinzi |
| Janssen Biotech, INC. | $4,677.21 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $3,970.00 | 2023-2024 | |
| Janssen Scientific Affairs, LLC | $2,185.00 | 2019 | |
| Seagen INC. | $1,466.46 | 2020-2023 | |
| Gilead Sciences, INC. | $524.01 | 2021-2024 | Trodelvy |
| Genentech USA, INC. | $211.59 | 2024-2025 | |
| Astrazeneca Uk Limited | $117.10 | 2025 | Imfinzi |
| Eli Lilly and Company | $113.00 | 2025 | |
| Eisai INC. | $110.74 | 2022-2023 | |
| Emd Serono, INC. | $93.87 | 2020 | |
| Sage Therapeutics, LLC | $74.81 | 2023 | |
| Astellas Pharma US INC | $60.00 | 2023 | Padcev |
6 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mamta Parikh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.